What Is Transurethral Resection of Bladder Tumor (TURBT)? If you have bladder cancer or suspected bladder cancer, your doctor has probably told you that you need a transurethral resection of the ...
Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...
“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...
MILAN — Photodynamic diagnosis-guided transurethral resection of bladder tumors did not reduce recurrence rates of non–muscle-invasive bladder cancer (NMIBC) in the longer term compared with standard ...
India Education Diary on MSN
Complex bladder cancer surgery successfully performed at JNMCH, AMU
Aligarh, Jan. 30 -- Aligarh : In a major medical achievement, doctors at Jawaharlal Nehru Medical College and Hospital (JNMCH), Aligarh Muslim University (AMU), successfully performed a complex ...
Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...
Investigators observe no significant difference between the surgical approaches in 1-year progression rates. En bloc resection has the potential to improve outcomes in patients with non-muscle ...
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...
A meta-analysis of RCTs supports holmium laser as safer and more effective in a few key aspects compared with the plasma technique for initial management of NMIBC. Holmium laser resection of ...
Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy. Patients with nonmetastatic ...
In the next frontier of immuno-oncology competition focusing on treatment around surgery, Bristol Myers Squibb has snatched another U.S. license for Opdivo—this time in bladder cancer. The FDA has ...
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results